Urticaria (Hives)

Table of Contents

1. What is Urticaria?
2. Types of Urticaria
3. Causes and Triggers
4. Symptoms and Distribution Patterns
5. Diagnosis and Scoring
6. Treatment Options
7. Natural and Lifestyle Approaches
8. Complications
9. Prevention and Trigger Control
10. Key Research Papers
11. PubMed Searches
12. Connections
13. Featured Videos

What is Urticaria?

Urticaria, commonly called hives, is a skin reaction characterized by raised, itchy welts (wheals) that appear suddenly on the skin. Individual lesions typically resolve within 24 hours without leaving a mark, but new ones may continue to form. When the underlying swelling extends deeper into the skin and subcutaneous tissue, it is called angioedema, which can involve the lips, eyelids, tongue, or throat and may become life-threatening.

Urticaria affects roughly 20% of people at some point in their lives. The condition is driven primarily by mast cell degranulation and the release of histamine, which causes characteristic vascular dilation and plasma leakage into the dermis. While most episodes are self-limited, roughly 1% of the population has chronic urticaria lasting more than six weeks.

Types of Urticaria

Acute Urticaria (less than 6 weeks)

• Duration: Symptoms last fewer than 6 weeks, most episodes resolve within days to a few weeks.
• Common causes: Infections (especially viral upper respiratory infections in children), foods (peanuts, tree nuts, shellfish, eggs, milk, wheat), medications (NSAIDs, antibiotics, ACE inhibitors), insect stings, latex, and blood transfusions.
• IgE-mediated allergy is the clearest mechanism — allergen cross-links IgE on mast cell surfaces, triggering rapid degranulation within minutes.
• Prognosis: Excellent — the majority of acute cases resolve spontaneously without recurrence.

Chronic Spontaneous Urticaria (CSU) — more than 6 weeks

• Definition: Wheals occurring on most days for more than 6 consecutive weeks with no identifiable external trigger.
• Unknown trigger in ~80% of patients — hence "spontaneous." This frustrates both patients and clinicians.
• Autoimmune mechanism in ~40–50%: IgG autoantibodies against the high-affinity IgE receptor (FcεRI) or against IgE itself activate mast cells independently of allergen.
• Associated conditions: Thyroid autoimmunity (Hashimoto's thyroiditis) is present in 10–30% of CSU patients; Helicobacter pylori and other chronic infections may play a role in some.
• Course: Spontaneous remission occurs in about 50% of patients within 1 year, and in about 80% within 5 years.

Chronic Inducible Urticaria (CindU)

• Dermographism (symptomatic dermatographism): Firm stroking of the skin raises a linear wheal within minutes. Affects up to 5% of the general population. Distinguished from simple dermatographism by accompanying itch.
• Cholinergic urticaria: Triggered by rise in core body temperature from exercise, hot baths, emotional stress, or spicy food. Small, 1–3 mm punctate wheals surrounded by large erythematous flares. Affects ~5% of young adults.
• Cold urticaria: Wheals appear upon cold exposure (cold air, water, food). Risk of systemic anaphylaxis with cold-water immersion (swimming) — patients should carry an epinephrine auto-injector.
• Solar urticaria: Rare reaction to UV or visible light wavelengths; wheals appear within minutes of sun exposure on uncovered skin.
• Pressure urticaria: Deep, painful swelling appearing 4–8 hours after sustained pressure (waistbands, tight shoes). Often misdiagnosed as cellulitis.
• Aquagenic urticaria: Very rare; small follicular papules with water contact at any temperature.

Causes and Triggers

• Foods: Peanuts, tree nuts, shellfish, fish, eggs, cow's milk, wheat; non-allergic pseudoallergens (histamine-rich foods — aged cheeses, wine, fermented products) can exacerbate CSU.
• Medications that worsen urticaria: NSAIDs (including aspirin) trigger non-IgE reactions via COX-1 inhibition in up to 30% of CSU patients; ACE inhibitors (block bradykinin degradation, worsening angioedema); opioids (direct mast cell degranulation).
• Infections: Viral URIs (most common trigger of acute urticaria in children), Helicobacter pylori, hepatitis B and C, Anisakis, parasites.
• Insect stings: Bee, wasp, and fire ant venom; IgE-mediated in most cases.
• Latex allergy: Type I IgE-mediated; important in healthcare workers and patients with spina bifida.
• Stress: Emotional or physical stress can precipitate or worsen CSU episodes.
• Hormonal changes: Estrogen fluctuations (menstrual cycle, pregnancy, oral contraceptives) are linked to urticaria exacerbations in some women.

Symptoms and Distribution Patterns

• Wheals: Raised, blanching, erythematous lesions ranging from a few millimeters to several centimeters. Pale center with surrounding flare. Each individual wheal lasts less than 24 hours by definition.
• Intense itch (pruritus): Often the most distressing symptom, worse in the evening and at night due to circadian patterns of skin temperature and histamine release.
• Angioedema: Deep, non-pitting swelling most often affecting lips, periorbital tissue, tongue, and pharynx. Can be painful rather than itchy. Present in ~50% of CSU patients. Laryngeal angioedema is a medical emergency.
• Distribution: Can appear anywhere on the body, including palms and soles. No fixed predilection site in CSU; inducible types follow the pattern of the physical stimulus.
• Time course: Acute urticaria — symptoms within minutes of trigger exposure, typically resolve within hours. CSU — daily or near-daily symptoms for weeks to years.
• Systemic symptoms (anaphylaxis): Hypotension, bronchospasm, nausea/vomiting, syncope — occur when mast cell activation is massive (severe IgE-mediated allergy). Requires immediate epinephrine.

Diagnosis and Scoring

Urticaria is primarily a clinical diagnosis based on history and skin examination. Laboratory workup is targeted by the history.

Clinical Criteria

• Wheals lasting fewer than 24 hours that resolve without residual discoloration (helps distinguish from urticarial vasculitis, where lesions last >24 hours and leave bruising).
• If skin biopsy is done (unusual in typical urticaria): perivascular and interstitial infiltrate of lymphocytes and eosinophils, mast cell degranulation, dilated capillaries.

Urticaria Activity Score (UAS7)

• Validated patient-reported tool: daily wheals (0–3) + itch severity (0–3) summed over 7 days. Max score = 42.
• Well-controlled CSU: UAS7 ≤6; moderate: 7–15; severe: 16–27; very severe: 28–42.
• Used to guide treatment escalation and monitor omalizumab response.

Laboratory Workup for CSU

• Routine (per EAACI/GA²LEN guidelines): Complete blood count (eosinophilia → parasite or drug reaction), CRP/ESR (elevated → suspect urticarial vasculitis), thyroid function and anti-TPO antibodies.
• Targeted by history: Total IgE, specific IgE to suspected allergens (foods, venom, latex); H. pylori breath test or stool antigen; hepatitis serology.
• Autologous serum skin test (ASST) or basophil activation test (BAT): Research tools to detect autoreactive urticaria; not required for clinical management.
• Inducible urticaria provocation tests: Ice cube test (cold urticaria), FricTest dermographometer (dermographism threshold), exercise challenge (cholinergic), UV monochromator (solar urticaria).

Differential Diagnosis

• Urticarial vasculitis: Wheals persist >24 hours, leave purpura or bruising; systemic symptoms (joint pain, nephritis); biopsy shows leucocytoclastic vasculitis.
• Mastocytosis / mast cell activation syndrome (MCAS): Recurrent multi-system reactions; elevated serum tryptase (baseline >20 ng/mL in systemic mastocytosis); skin lesions (urticaria pigmentosa).
• Hereditary angioedema (HAE): C1-esterase inhibitor deficiency; recurrent angioedema WITHOUT wheals; does NOT respond to antihistamines; treat with specific HAE therapies (icatibant, C1-INH concentrate, lanadelumab).
• Erythema multiforme: Target lesions; persistent (>24 hours); often triggered by herpes simplex.

Treatment Options

The stepwise treatment ladder is based on international EAACI/GA²LEN/EDF/WAO guidelines for urticaria (2022 update).

Step 1 — Non-sedating H1 Antihistamines (Standard Dose)

• Second-generation antihistamines — cetirizine 10 mg, loratadine 10 mg, fexofenadine 180 mg, bilastine 20 mg, or rupatadine — are the first-line therapy for all urticaria types.
• Taken daily (not just during flares) for chronic urticaria.
• Controls symptoms in ~50% of CSU patients at standard dose.

Step 2 — Up-dosing Non-sedating Antihistamines (Up to 4× Licensed Dose)

• If standard dose fails after 2–4 weeks, up-dosing to 4× is supported by evidence and recommended before escalating to biologics.
• Example: cetirizine 40 mg/day, fexofenadine 720 mg/day.
• Additional response in ~20–30% of patients who failed standard dose.
• First-generation antihistamines (diphenhydramine, hydroxyzine) are NOT recommended for regular use — sedating, impair driving, cause tolerance, and risk anticholinergic side effects.

Step 3 — Add Omalizumab (Anti-IgE Monoclonal Antibody)

• Omalizumab (Xolair) 300 mg subcutaneously every 4 weeks is the standard add-on therapy for antihistamine-refractory CSU.
• ASTERIA II Trial (Maurer et al., NEJM 2013, PMID 23432141): 323 patients with refractory CSU randomized to omalizumab 75/150/300 mg or placebo every 4 weeks for 24 weeks. Omalizumab 300 mg reduced weekly itch severity score by 8.55 vs 5.13 for placebo (p<0.001). Complete response (UAS7=0) in 36% vs 9% (placebo). Rapid onset: benefit seen by week 4.
• Approved for adults and adolescents ≥12 years with refractory CSU.
• Generally well-tolerated; rare risk of anaphylaxis within 2 hours of injection (patients monitored post-injection).
• Dose and duration: 300 mg q4w; assess response at 6 months; attempt dose reduction or discontinuation annually.

Step 4 — Add Cyclosporine A

• Immunosuppressive agent for omalizumab non-responders or when omalizumab is unavailable.
• Dose: 3–5 mg/kg/day for 3–6 months; taper to lowest effective dose.
• Monitor blood pressure, renal function, and drug interactions.
• Effective in ~70–80% of autoimmune CSU (autoreactive subtype).

Short-course Corticosteroids

• Oral prednisolone 20–40 mg/day for 3–5 days is appropriate for severe acute urticaria or CSU flares.
• Not for long-term use — significant adverse effects preclude maintenance therapy.

Avoid Triggers of Worsening

• Avoid NSAIDs and aspirin in CSU — pseudoallergic reaction worsens symptoms in ~30% of patients.
• ACE inhibitors and angiotensin II receptor blockers should be avoided in patients with angioedema.
• Eliminate pseudoallergen-rich diet (histamine, food additives) as a therapeutic trial in refractory CSU.

Inducible Urticaria — Specific Therapies

• Cold urticaria: Antihistamines (rupatadine has best evidence); carry epinephrine; avoid cold-water swimming until symptoms controlled.
• Cholinergic urticaria: Antihistamines; danazol (anabolic steroid) in refractory cases; heat desensitization protocols.
• Dermographism: Low-dose antihistamines reduce threshold; often manageable.
• Solar urticaria: High-SPF broad-spectrum sunscreen; antihistamines; narrowband UVB desensitization.

Natural and Lifestyle Approaches

• Low-pseudoallergen (Mainz) diet: Avoidance of histamine-rich foods (aged cheeses, red wine, canned fish, sauerkraut, vinegar), artificial additives (tartrazine, benzoates, sulfites), and natural salicylates for 3–4 weeks as a diagnostic and therapeutic trial. Clinical improvement in ~30–50% of refractory CSU patients in observational studies.
• Vitamin D supplementation: Several RCTs have shown that vitamin D3 (at least 4000 IU/day) may reduce UAS7 and antihistamine requirements in CSU patients with vitamin D deficiency. Zuberbier et al. 2015 review notes plausible immune-modulating rationale via vitamin D receptor on mast cells.
• Quercetin: Natural flavonoid that stabilizes mast cell membranes and inhibits histamine release in vitro. Human RCT evidence limited; 500–1000 mg/day used empirically alongside antihistamines.
• Stress reduction: Cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) reduce perceived itch severity and anxiety in chronic urticaria. Psychosomatic dermatology programs show measurable UAS7 improvement.
• Avoid alcohol: Ethanol directly degranulates mast cells and vasodilates skin, reliably worsening acute urticaria episodes.
• Cooling measures: Cold compresses, cool showers (caution in cold urticaria), lightweight clothing reduce itch intensity without medication; calamine lotion provides topical relief.
• H. pylori eradication: In patients with CSU and confirmed H. pylori infection, eradication therapy leads to remission in a subset of patients (meta-analyses show modest but significant benefit).

Complications

• Anaphylaxis: The most serious complication of acute urticaria, particularly IgE-mediated food or venom allergy. Risk of hypotension, bronchospasm, and cardiovascular collapse. Requires epinephrine (0.3–0.5 mg IM) as first-line treatment.
• Laryngeal angioedema: Throat swelling causing stridor and respiratory compromise; can be rapidly fatal without airway management and epinephrine.
• Sleep disruption: Intense nocturnal pruritus severely impairs sleep quality, leading to fatigue, daytime impairment, and mood disorders. Quality-of-life scales (Dermatology Life Quality Index) show CSU causes impairment comparable to coronary artery disease.
• Anxiety and depression: Prevalence of anxiety disorders is 2–3× higher in chronic urticaria patients than general population; depression co-occurs in ~20%. Uncertainty about triggers amplifies psychological burden.
• Skin lichenification: Repeated scratching of intense wheals can cause secondary skin thickening, hyperpigmentation, and excoriations.
• Medication side effects: Long-term first-generation antihistamine use (sometimes self-medicated) causes cognitive impairment, dry mouth, urinary retention, and fall risk in the elderly.

Prevention and Trigger Control

• Keep a symptom diary: Record foods, medications, activities, stress levels, and environmental exposures alongside wheal onset to identify reproducible triggers — especially valuable in identifying pseudoallergen sensitivities.
• Allergy testing and avoidance: Skin prick testing or specific IgE blood tests for suspected allergens; strict avoidance of confirmed triggers (e.g., shellfish, peanuts) prevents IgE-mediated acute episodes.
• Carry epinephrine auto-injector: Mandatory for any patient with confirmed food allergy, cold urticaria, or prior anaphylaxis episode. Annual training on injection technique.
• Medication review: At every encounter, review medications for NSAIDs, ACE inhibitors, and opioids that worsen urticaria; discuss safer alternatives with the prescribing physician.
• Protective clothing for inducible types: Cold urticaria — warm clothing, gloves, face protection in cold weather; solar urticaria — UV-protective clothing (UPF 50+) and broad-spectrum sunscreen.
• Treat underlying infections: H. pylori eradication, treatment of chronic sinusitis or dental infections, and anthelminthic therapy for intestinal parasites may resolve or reduce CSU in specific patients.
• Thyroid management: Treating Hashimoto's thyroiditis with levothyroxine may improve CSU in autoimmune subtype, though evidence is mixed.

Key Research Papers

1. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935. PMID 23432141
2. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. PMID 29336054
3. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy (ASTERIA I). J Allergy Clin Immunol. 2013;132(1):101-109. PMID 23810097
4. Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599-1604. PMID 8178518
5. Sabroe RA, Seed PT, Francis DM, et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol. 1999;40(3):443-450. PMID 10098966
6. Baiardini I, Braido F, Bindslev-Jensen C, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA²LEN taskforce position paper. Allergy. 2011;66(7):840-844. PMID 20560904
7. Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307-1313. PMID 21982432
8. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria. J Allergy Clin Immunol. 2009;123(3):672-679. PMID 18804278
9. Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-dimer. J Allergy Clin Immunol. 2015;135(5):1401-1403. PMID 25213156
10. Staubach P, Magerl M, Metz M, et al. Randomized, double-blind, placebo-controlled trial on the use of cyclosporin A in chronic spontaneous urticaria. J Dermatol. 2010;37(8):740-747. PMID 20534107
11. Nettis E, Dambra P, D'Oronzio L, et al. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol. 2001;137(1):99-100. PMID 11674327
12. Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777-780. PMID 18647173

Back to Table of Contents

PubMed Searches

Curated PubMed topic searches of peer-reviewed literature on urticaria and hives.

1. PubMed: Chronic spontaneous urticaria treatment
2. PubMed: Omalizumab for urticaria RCT
3. PubMed: Urticaria autoimmune mechanism
4. PubMed: Chronic inducible urticaria
5. PubMed: Urticaria angioedema antihistamine
6. PubMed: Urticaria quality of life UAS7
7. PubMed: Cholinergic urticaria
8. PubMed: H. pylori and urticaria
9. PubMed: Mast cell histamine degranulation
10. PubMed: Urticaria thyroid autoimmunity

Back to Table of Contents

Connections

• Eczema
• Contact Dermatitis
• Psoriasis
• Allergies
• Anaphylaxis
• Rosacea
• Vitiligo
• Hashimoto's Thyroiditis
• SIBO
• Vitamin D3
• Zinc
• Quercetin
• Stress Management
• Acne
• Hidradenitis Suppurativa
• Leaky Gut

Back to Table of Contents

×

Featured Videos